UNIVERSITAS
GADJAH MADA
**Eksplorasi Aktivitas Antikanker Analog Kurkumin PGV-1 Dan CCA-1.1 Pada Sel Karsinoma Hepatoseluler
Yang Mengekspresikan MYCN**
Moordiani, Prof. Dr. apt. Ratna Asmah Susidarti, M.S.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

DAFTAR PUSTAKA

Adan, A., Kiraz, Y., dan Baran, Y., 2016. Cell Proliferation and Cytotoxicity Assays. *Current Pharmaceutical Biotechnology*, **17**: 1213–1221.

Afri, M., Frimer, A.A., dan Cohen, Y., 2004. Active Oxygen Chemistry within The Liposomal Bilayer: Part IV: Locating 2′,7′-dichlorofluorescein (DCF), 2′,7′-dichlorodihydrofluorescein (DCFH) and 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) in The Lipid Bilayer. *Chemistry and Physics of Lipids*, **131**: 123–133.

Alberts, B., Heald, R., Johnson, A., Morgan, D., Raff, M., Roberts, K., dkk., 2022. *Molecular Biology of The Cell*, 7th ed. W. W. Norton & Company.

Arfin, S., Jha, N.K., Jha, S.K., Kesari, K.K., Ruokolainen, J., Roychoudhury, S., dkk., 2021. Oxidative stress in cancer cell metabolism. *Antioxidants*, **10**: 642.

Armstrong, M.B., Mody, R.J., Christian Ellis, D., Hill, A.B., Erichsen, D.A., dan Wechsler, D.S., 2013. N-Myc Differentially Regulates Expression of MXI1 Isoforms in Neuroblastoma. *Neoplasia (United States)*, **15**: 1363–1370.

Balogh, J., Victor 3rd, D., Asham, E.H., Burroughs, S.G., Boktour, M., Saharia, A., dkk., 2016. Hepatocellular Carcinoma: A Review. *Journal of Hepatocellular Carcinoma*, **3**: 41–53.

Barnum, K.J. dan O'Connell, M.J., 2014. Cell Cycle Regulation by Checkpoints. *Methods in Molecular Biology (Clifton, N.J.)*, **1170**: 29–40.

Bhardwaj, N., Das, G., dan Srinivasan, R., 2023. Neuroblastoma-Derived v-myc Avian Myelocytomatosis Viral Related Oncogene or MYCN Gene. *Journal of Clinical Pathology*, **76**: 518–523.

Billimoria, R. dan Bhatt, P., 2023. Senescence in Cancer: Advances in Detection and Treatment Modalities. *Biochemical Pharmacology*, **215**: 115739.

Bosch, A., Li, Z., Bergamaschi, A., Ellis, H., Toska, E., Prat, A., dkk., 2015. PI3K Inhibition Results in Enhanced Estrogen Receptor Function and Dependence in Hormone Receptor-Positive Breast Cancer. *Science Translational Medicine*, **7**: 283ra51.

Bouchard, C., Dittrich, O., Kiermaier, A., Dohmann, K., Menkel, A., Eilers, M., dkk., 2001. Regulation of Cyclin D2 Gene Expression by the Myc/Max/Mad network: Myc-Dependent TRRAP Recruitment and Histone Acetylation at The Cyclin D2 Promoter. *Genes & Development*, **15**: 2042–2047.

Bretones, G., Delgado, M.D., dan León, J., 2015. Myc and Cell Cycle Control. *Biochimica et Biophysica Acta - Gene Regulatory Mechanisms*, **1849**: 506–516.

Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., dan Alimonti, A., 2019. Cellular Senescence: Aging, Cancer, and Injury. *Physiological Reviews*, **99**: 1047–1078.

Calderaro, J., Ziol, M., Paradis, V., dan Zucman-Rossi, J., 2019. Molecular and histological correlations in liver cancer. *Journal of Hepatology*, **71**: 616–630.

Cao, Y., Liu, Y., Shang, L., Wei, W., Shen, Y., Gu, Q., dkk., 2020. Decitabine and all-trans retinoic acid synergistically exhibit cytotoxicity against elderly AML patients via miR-34a/MYCN axis. *Biomedicine & Pharmacotherapy*, **125**: 109878.

UNIVERSITAS
GADJAH MADA
**Eksplorasi Aktivitas Antikanker Analog Kurkumin PGV-1 Dan CCA-1.1 Pada Sel Karsinoma Hepatoseluler
Yang Mengekspresikan MYCN**
Moordiani, Prof. Dr. apt. Ratna Asmah Susidarti, M.S.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Chambers, C.R., Ritchie, S., Pereira, B.A., dan Timpson, P., 2021. Overcoming the senescence-associated secretory phenotype (SASP): a complex mechanism of resistance in the treatment of cancer. *Molecular Oncology*, **15**: 3242–3255.

Chang, H.-H., Tseng, Y.-F., Lu, M.-Y., Yang, Y.-L., Chou, S.-W., Lin, D.-T., dkk., 2020. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients. *Modern Pathology*, **33**: 531–540.

Chao, J., Zhao, S., dan Sun, H., 2020. Dedifferentiation of hepatocellular carcinoma: Molecular mechanisms and therapeutic implications. *American Journal of Translational Research*, **12**: 2099–2109.

Chen, H. dan Li, W., 2021. Advances in mechanism of sorafenib resistance in treatment of primary hepatic carcinoma; [原发性肝癌治疗中索拉非尼耐药发生机制的研究进展]. *Tumor*, **41**: 435 – 443.

Chen, H., Liu, H., dan Qing, G., 2018. Targeting oncogenic Myc as a strategy for cancer treatment. *Signal Transduction and Targeted Therapy*, **3**: 1–7.

Chen, M.-C., Kuo, Y.-C., Hsu, C.-M., Chen, Y.-L., Shen, C.-C., Teng, C.-M., dkk., 2017. The apoptotic mechanisms of MT-6, a mitotic arrest inducer, in human ovarian cancer cells. *Scientific Reports*, **7**: 46149.

Crowley, L.C., Scott, A.P., Marfell, B.J., Boughaba, J.A., Chojnowski, G., dan Waterhouse, N.J., 2016. Measuring cell death by propidium iodide uptake and flow cytometry. *Cold Spring Harbor Protocols*, **2016**: 647–651.

Da'i, M., Suhendi, A., Meiyanto, E., A JENIE, U., dan Kawaichi, M., 2017. Apoptosis Induction Effect of Curcumin and Its Analogs Pentagamavunon-0 and Pentagamavunon-1 on Cancer Cell Lines. *Asian Journal of Pharmaceutical and Clinical Research*, **10**: 373–376.

Dang, C. V, O'Donnell, K.A., Zeller, K.I., Nguyen, T., Osthus, R.C., dan Li, F., 2006. The c-Myc target gene network. *Seminars in Cancer Biology*, **16**: 253–264.

Darvesh, A.S., Aggarwal, B.B., dan Bishayee, A., 2012. Curcumin and liver cancer: a review. *Current Pharmaceutical Biotechnology*, **13**: 218–228.

Darzynkiewicz, Z., Halicka, H.D., dan Zhao, H., 2010. Analysis of cellular DNA content by flow and laser scanning cytometry. *Advances in experimental medicine and biology*, **676**: 137–147.

Davalli, P., Mitic, T., Caporali, A., Lauriola, A., dan D'Arca, D., 2016. ROS, Cell Senescence, and Novel Molecular Mechanisms in Aging and Age-Related Diseases. *Oxidative Medicine and Cellular Longevity*, **2016**: 3565127.

De Marco Zompit, M. dan Stucki, M., 2021. Mechanisms of genome stability maintenance during cell division. *DNA Repair*, **108**: 103215.

Delfarah, A., Hartel, N.G., Zheng, D., Yang, J., dan Graham, N.A., 2021. Identification of a Proteomic Signature of Senescence in Primary Human Mammary Epithelial Cells. *Journal of Proteome Research*, **20**: 5169–5179.

Digre, A. dan Lindskog, C., 2023. The human protein atlas-Integrated omics for single cell mapping of the human proteome. *Protein Science : A Publication of The Protein Society*, **32**: e4562.

Dimitroulis, D., Damaskos, C., Valsami, S., Davakis, S., Garmpis, N., Spartalis, E.,

UNIVERSITAS
GADJAH MADA
Eksplorasi Aktivitas Antikanker Analog Kurkumin PGV-1 Dan CCA-1.1 Pada Sel Karsinoma Hepatoseluler
Yang Mengekspresikan MYCN
Moordiani, Prof. Dr. apt. Ratna Asmah Susidarti, M.S.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

dkk., 2017. From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. *World Journal of Gastroenterology*, **23**: 5282–5294.

Donne, R., Sangouard, F., Celton-Morizur, S., dan Desdouets, C., 2021. Hepatocyte Polyploidy: Driver or Gatekeeper of Chronic Liver Diseases. *Cancers*, .

Duncan, A.W., 2013. Aneuploidy, polyploidy and ploidy reversal in the liver. *Seminars in Cell & Developmental Biology*, **24**: 347–356.

Eberherr, C., Beck, A., Vokuhl, C., Becker, K., Häberle, B., Von Schweinitz, D., dkk., 2019. Targeting excessive MYCN expression using MLN8237 and JQ1 impairs the growth of hepatoblastoma cells. *International Journal of Oncology*, **54**: 1853–1863.

Falconieri, M.C., Adamo, M., Monasterolo, C., Bergonzi, M.C., Coronnello, M., dan Bilia, A.R., 2017. New Dendrimer-Based Nanoparticles Enhance Curcumin Solubility. *Planta Medica*, **83**: 420–425.

Fan, C.-W., Luo, L., Li, M.-S., Gu, Y.-Q., Fang, Y.-L., Qin, F., dkk., 2024. Sesquilignans PD from Zanthoxylum nitidum var. tomentosum exerts antitumor effects via the ROS/MAPK pathway in liver cancer cells. *Journal of Asian Natural Products Research*, **26**: 1530–1542.

Faria, S.C., Hwu, W.-J., dan Curley, S.A., 2022. *Metastases to Abdominal-Pelvic Organs*, Oncologic Imaging: A Multidisciplinary Approach. Elsevier.

Fernandes, D.P., Pimentel, M.M.L., Santos, F.A.D.O.S., Praxedes, É.A., Brito, P.D.D.E., LIMA, M.A., dkk., 2018. Hematological and biochemical profile of BALB/c nude and C57BL/6 SCID female mice after ovarian xenograft. *Anais da Academia Brasileira de Ciências*, .

Fu, L., Wang, S., Zhang, N., Lin, Y., Zhang, S., Mao, Y., dkk., 2025. Breaking the vicious cycle of cellular senescence and ROS via a mitochondrial-targeted hydrogel for aged bone regeneration. *Chemical Engineering Journal*, **503**: 158540.

Fujimaki, K. dan Yao, G., 2020. Cell dormancy plasticity: Quiescence deepens into senescence through a dimmer switch. *Physiological Genomics*, **52**: 558–562.

Fukuyama, K., Asagiri, M., Sugimoto, M., Tsushima, H., Seo, S., Taura, K., dkk., 2021. Gene expression profiles of liver cancer cell lines reveal two hepatocyte-like and fibroblast-like clusters. *PLoS ONE*, **16**: 1–17.

Garić, D., Dumut, D.C., Centorame, A., dan Radzioch, D., 2023. Western Blotting with Fast SDS-PAGE and Semi-Dry Protein Transfer. *Current Protocols*, **3**: e833.

Gast, S.-M., Kim, Y., dan Schmidt-Wolf, I.G.H., 2013. Wnt/β-catenin signaling pathway: A target for novel therapeutic approaches in multiple myeloma. *Drugs of the Future*, **38**: 757–763.

Gnanaprakasam, J.N.R. dan Wang, R., 2017. MYC in regulating immunity: Metabolism and beyond. *Genes*, **8**: 88.

Guo, J., Yan, W., Duan, H., Wang, D., Zhou, Y., Feng, D., dkk., 2024. Therapeutic Effects of Natural Products on Liver Cancer and Their Potential Mechanisms. *Nutrients*, **16**: 1642.

Han, H., Jain, A.D., Truica, M.I., Izquierdo-Ferrer, J., Anker, J.F., Lysy, B., dkk., 2019. Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance

UNIVERSITAS
GADJAH MADA
Eksplorasi Aktivitas Antikanker Analog Kurkumin PGV-1 Dan CCA-1.1 Pada Sel Karsinoma Hepatoseluler
Yang Mengekspresikan MYCN
Moordiani, Prof. Dr. apt. Ratna Asmah Susidarti, M.S.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Immunotherapy. *Cancer Cell*, **36**: 483-497.e15.

Hanahan, D., 2022. Hallmarks of Cancer: New Dimensions. *Cancer Discovery*, **12**: 31–46.

Hanahan, D. dan Weinberg, R.A., 2011. Hallmarks of cancer: the next generation. *Cell*, **144**: 646–674.

Hermawan, A., Fitriasari, A., Junedi, S., Ikawati, M., Haryanti, S., Widaryanti, B., dkk., 2011. PGV-0 and PGV-1 Increased Apoptosis Induction of Doxorubicin on MCF-7 Breast Cancer Cells. *Pharmacon: Jurnal Farmasi Indonesia*, **12**: 55–59.

Hsu, C.-W., Chen, Y.-C., Su, H.-H., Huang, G.-J., Shu, C.-W., Wu, T.T.-L., dkk., 2017. Targeting TPX2 Suppresses the Tumorigenesis of Hepatocellular Carcinoma Cells Resulting in Arrested Mitotic Phase Progression and Increased Genomic Instability. *Journal of Cancer*, **8**: 1378–1394.

Ito, H., Nakamae, I., Kato, J.-Y., dan Yoneda-Kato, N., 2021. Stabilization of fatty acid synthesis enzyme acetyl-CoA carboxylase 1 suppresses acute myeloid leukemia development. *The Journal of Clinical Investigation*, **131**: n. pag.

Japanese Collection of Research Bioresources (JCRB) Cell Bank, n.d. 'Detailed Information [JCRB1031]-JHH-7 cells', . URL: https://cellbank.nibn.go.jp/~cellbank/en/search_res_det.cgi?ID=2136 (diakses tanggal 10/3/2023a).

Japanese Collection of Research Bioresources (JCRB) Cell Bank, n.d. 'Detailed Information [JCRB0403]-HuH-7 cells', . URL: https://cellbank.nibn.go.jp/~cellbank/en/search_res_det.cgi?ID=385 (diakses tanggal 10/3/2023b).

Ji, J.-L., Huang, X.-F., dan Zhu, H.-L., 2012. Curcumin and its formulations: Potential anti-cancer agents. *Anti-Cancer Agents in Medicinal Chemistry*, **12**: 210–218.

Kamitani, N., Nakamae, I., Yoneda-Kato, N., Kato, J.-Y., dan Sho, M., 2022. Preclinical evaluation of pentagamavunone-1 as monotherapy and combination therapy for pancreatic cancer in multiple xenograft models. *Scientific Reports*, **12**: 22419.

Kementerian Kesehatan Republik Indonesia, 2022. Pedoman Tatalaksana Karsinoma Sel Hati pada Dewasa. *Kementerian Kesehatan RI*, 1–55.

Kluz, N., Grabowska, H., Chmiel, P., Rynkiewicz, K., Skrobucha, A., Wysokińska, E., dkk., 2025. Platelets in Hepatocellular Carcinoma—From Pathogenesis to Targeted Therapy. *Cancers*, **17**: 2391.

Kumar, A. dan Thirumurugan, K., 2023. Understanding cellular senescence: pathways involved, therapeutics and longevity aiding. *Cell Cycle*, **22**: 2324–2345.

Kurien, B.T. dan Scofield, R.H., 2006. Western blotting. *Methods*, **38**: 283–293.

Larasati, Y.A., Yoneda-Kato, N., Nakamae, I., Yokoyama, T., Meiyanto, E., dan Kato, J.-Y., 2018. Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth. *Scientific Reports*, **8**: 2039.

Lee, M., Seok, J., Saha, S.K., Cho, S., Jeong, Y., Gil, M., dkk., 2023. Alterations and Co-Occurrence of C-MYC, N-MYC, and L-MYC Expression are Related to Clinical Outcomes in Various Cancers. *International Journal of Stem Cells*,

UNIVERSITAS
GADJAH MADA
**Eksplorasi Aktivitas Antikanker Analog Kurkumin PGV-1 Dan CCA-1.1 Pada Sel Karsinoma Hepatoseluler
Yang Mengekspresikan MYCN**
Moordiani, Prof. Dr. apt. Ratna Asmah Susidarti, M.S.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

16: 215–233.

Lestari, B., Nakamae, I., Yoneda-Kato, N., Morimoto, T., Kanaya, S., Yokoyama, T., dkk., 2019. Pentagamavunon-1 (PGV-1) inhibits ROS metabolic enzymes and suppresses tumor cell growth by inducing M phase (prometaphase) arrest and cell senescence. *Scientific Reports*, **9**: 14867.

Liu, B., Peng, Z., Zhang, H., Zhang, N., Liu, Z., Xia, Z., dkk., 2025. Regulation of cellular senescence in tumor progression and therapeutic targeting: mechanisms and pathways. *Molecular Cancer*, **24**: 106.

Liu, D., Zhang, J., Guo, Z.-Y., Xue, L.-X., dan Wang, Y.-Q., 2024. Factors Influencing Flow Cytometry-based Cell Cycle Detection and Analysis of Various Immune Cell Subpopulations. *Chinese Journal of Biochemistry and Molecular Biology*, **40**: 1308–1316.

Liu, F., Liao, Z., dan Zhang, Z., 2023. MYC in liver cancer: mechanisms and targeted therapy opportunities. *Oncogene*, **42**: 3303 – 3318.

Liu, R., Shi, P., Wang, Z., Yuan, C., dan Cui, H., 2021. Molecular Mechanisms of MYCN Dysregulation in Cancers. *Frontiers in Oncology*, .

Liu, Z., Chen, S.S., Clarke, S., Veschi, V., dan Thiele, C.J., 2021. Targeting MYCN in Pediatric and Adult Cancers. *Frontiers in Oncology*, **10**: 1–15.

Llovet, J.M., Kelley, R.K., Villanueva, A., Singal, A.G., Pikarsky, E., Roayaie, S., dkk., 2021. Hepatocellular carcinoma. *Nature reviews. Disease primers*, **7**: 6.

Man, S., Luo, C., Yan, M., Zhao, G., Ma, L., dan Gao, W., 2021. Treatment for liver cancer: From sorafenib to natural products. *European Journal of Medicinal Chemistry*, **224**: 113690.

Mani, S., Swargiary, G., dan Ralph, S.J., 2022. Targeting the redox imbalance in mitochondria: A novel mode for cancer therapy. *Mitochondrion*, **62**: 50–73.

Mathsyaraja, H. dan Eisenman, R.N., 2016. Parsing Myc Paralogs in Oncogenesis. *Cancer Cell*, **29**: 1–2.

Meiyanto, E., Husnaa, U., Kastian, R.F., Putri, H., Larasati, Y.A., Khumaira, A., dkk., 2021. The Target Differences of Anti-Tumorigenesis Potential of Curcumin and its Analogues Against HER-2 Positive and Triple-Negative Breast Cancer Cells. *Advanced Pharmaceutical Bulletin*, **11**: 188–196.

Meiyanto, E., Putri, D.D.P., Susidarti, R.A., Murwanti, R., Sardjiman, Fitriasari, A., dkk., 2014. Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation. *Asian Pacific Journal of Cancer Prevention : APJCP*, **15**: 179–184.

Meiyanto, E., Putri, H., Arum Larasati, Y., Yudi Utomo, R., Istighfari Jenie, R., Ikawati, M., dkk., 2019. Anti-proliferative and Anti-metastatic Potential of Curcumin Analogue, Pentagamavunon-1 (PGV-1), Toward Highly Metastatic Breast Cancer Cells in Correlation with ROS Generation. *Advanced Pharmaceutical Bulletin*, **9**: 445–452.

Meiyanto, E., Septisetyani, E.P., Larasati, Y.A., dan Kawaichi, M., 2018. Curcumin Analog Pentagamavunon-1 (PGV-1) Sensitizes Widr Cells to 5-Fluorouracil through Inhibition of NF-κB Activation. *Asian Pacific Journal of Cancer Prevention : APJCP*, **19**: 49–56.

Meyer, N. dan Penn, L.Z., 2008. Reflecting on 25 years with MYC. *Nature reviews.*

UNIVERSITAS
GADJAH MADA
**Eksplorasi Aktivitas Antikanker Analog Kurkumin PGV-1 Dan CCA-1.1 Pada Sel Karsinoma Hepatoseluler
Yang Mengekspresikan MYCN**
Moordiani, Prof. Dr. apt. Ratna Asmah Susidarti, M.S.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Cancer, **8**: 976–990.

Milczarek, M., 2020. The premature senescence in breast cancer treatment strategy. *Cancers*, **12**: 1–22.

Mohan, H., Vandna, Soni, S., dan Syed, S., 2022. *Targeting Reactive Oxygen Species (ROS) for Cancer Therapy*, Handbook of Oxidative Stress in Cancer: Therapeutic Aspects: Volume 1.

Moon, R.T., 2005. Wnt/beta-catenin pathway. *Science's STKE : signal transduction knowledge environment*, **2005**: cm1.

Musaie, K., Abbaszadeh, S., Marais, K., Nosrati-Siahmazgi, V., Rezaei, S., Xiao, B., dkk., 2025. H2O2-Generating Advanced Nanomaterials for Cancer Treatment. *Advanced Functional Materials*, **35**: 2425866.

Nakamura, H. dan Takada, K., 2021. Reactive oxygen species in cancer: Current findings and future directions. *Cancer Science*, **112**: 3945–3952.

Nau, M.M., Brooks, B.J., Battey, J., Sausville, E., Gazdar, A.F., Kirsch, I.R., dkk., 1985. L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. *Nature*, **318**: 69–73.

Nousis, L., Kanavaros, P., dan Barbouti, A., 2023. Oxidative stress-induced cellular senescence: is labile iron the connecting link? *Antioxidants*, **12**: 1250.

Nováková, E., Zima, J., Špaglová, M., Labudová, M., dan Šupolíková, M., 2024. Synergistic Antiproliferative Effects of Chondroitin Sulfate and Fucoidan in Tumor-derived Spheroids: Insights From a 3D Cell Culture Approach. *European Pharmaceutical Journal*, **71**: 25–33.

Novitasari, D., Jenie, R., Kato, J.Y., dan Meiyanto, E., 2023a. Chemoprevention curcumin analog 1.1 promotes metaphase arrest and enhances intracellular reactive oxygen species levels on TNBC MDA-MB-231 and HER2-positive HCC1954 cells. *Research in Pharmaceutical Sciences*, **18**: 358–370.

Novitasari, D., Jenie, R.I., Utomo, R.Y., Kato, J.Y., dan Meiyanto, E., 2021a. CCA-1.1, a Novel Curcumin Analog, Exerts Cytotoxic anti- Migratory Activity toward TNBC and HER2-Enriched Breast Cancer Cells. *Asian Pacific Journal of Cancer Prevention : APJCP*, **22**: 1827–1836.

Novitasari, D., Jenie, R.I., Wulandari, F., Utomo, R.Y., Putri, D.D.P., Kato, J., dkk., 2021b. A Curcumin-like structure (CCA-1.1) induces permanent mitotic arrest (Senescence) on Triple-negative breast cancer (TNBC) cells, 4T1. *Research Journal of Pharmacy and Technology*, **14**: 4375–82.

Novitasari, D., Kato, J. ya, Ikawati, M., Putri, D.D.P., Wulandari, F., Widyarini, S., dkk., 2023b. PGV-1 permanently arrests HepG2 cells in M phase and inhibits DMH-induced liver carcinogenesis in rats. *Journal of Applied Pharmaceutical Science*, **13**: 204–211.

Novitasari, D., Nakamae, I., Istighfari Jenie, R., Yoneda-Kato, N., Kato, J., dan Meiyanto, E., 2024. Pentagamavunone-1 inhibits aggressive breast cancer cell proliferation through mitotic catastrophe and ROS-mediated activities: in vitro and in vivo studies. *Saudi Pharmaceutical Journal*, **32**: 101892.

Novitasari, D., Nakamae, I., Yoneda-Kato, N., Meiyanto, E., dan Kato, J., 2025. Pentagamavunone-1 targets excessive MYCN/NCYM expression mediated by mitotic arrest to suppress hepatocellular carcinoma proliferation. *Cancer Gene Therapy*, **32**: 1233–1244.

UNIVERSITAS
GADJAH MADA
**Eksplorasi Aktivitas Antikanker Analog Kurkumin PGV-1 Dan CCA-1.1 Pada Sel Karsinoma Hepatoseluler
Yang Mengekspresikan MYCN**
Moordiani, Prof. Dr. apt. Ratna Asmah Susidarti, M.S.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Novitasari, D., Wulandari, F., Jenie, R.I., Utomo, R.Y., Kato, J.-Y., dan Meiyanto, E., 2021c. A new curcumin analog, CCA-1.1, induces cell cycle arrest and senescence toward ER-positive breast cancer cells. *International Journal of Pharmaceutical Research*, **13**: 1–9.

Nugraheni, N., Lestari, B., Meiyanto, E., dan Utomo, R.Y., 2025. Effect of PGV-1 on Apoptosis via Mitotic Arrest and Senescence in Polyploid Giant Cancer Cells of Hepatocellular Carcinoma JHH4. *Turkish Journal of Pharmaceutical Sciences*, **22**: 170–177.

Nurse, P., 2000. A Long Twentieth Century of the Cell Cycle and Beyond. *Cell*, **100**: 71–78.

Ozakyol, A., 2017. Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology). *Journal of Gastrointestinal Cancer*, **48**: 238–240.

Pavlova, G. V, Golbin, D.A., Kubyshkina, V.E., Galkin, M. V, Pronin, I.N., dan Karandashov, I. V, 2022. Cell cultures of human CNS tumors as in vitro model for individualized therapeutic approach. *Zhurnal Voprosy Nejrokhirurgii Imeni N.N. Burdenko*, **86**: 84–90.

Qin, X.-Y., Shirakami, Y., Honda, M., Yeh, S.-H., Numata, K., Lai, Y.-Y., dkk., 2024. Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence. *International Journal of Cancer*, **155**: 582–594.

Qin, X.-Y., Su, T., Yu, W., dan Kojima, S., 2020. Lipid desaturation-associated endoplasmic reticulum stress regulates MYCN gene expression in hepatocellular carcinoma cells. *Cell Death & Disease*, **11**: 66.

Qin, X.-Y., Suzuki, H., Honda, M., Okada, H., Kaneko, S., Inoue, I., dkk., 2018. Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid. *Proceedings of the National Academy of Sciences of the United States of America*, **115**: 4969–4974.

Rahl, P.B. dan Young, R.A., 2014. MYC and transcription elongation. *Cold Spring Harbor Perspectives in Medicine*, **4**: a020990.

Raieli, S., Di Renzo, D., Lampis, S., Amadesi, C., Montemurro, L., Pession, A., dkk., 2021. MYCN Drives a Tumor Immunosuppressive Environment Which Impacts Survival in Neuroblastoma. *Frontiers in Oncology*, **11**: 625207.

Ramayanti, O., Brinkkemper, M., Verkuijlen, S.A.W.M., Ritmaleni, L., Go, M.L., dan Middeldorp, J.M., 2018. Curcuminoids as EBV Lytic Activators for Adjuvant Treatment in EBV-Positive Carcinomas. *Cancers*, **10**: 89.

Ren, B., Cam, H., Takahashi, Y., Volkert, T., Terragni, J., Young, R.A., dkk., 2002. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. *Genes & Development*, **16**: 245–256.

Ross, S.M., 2024. Turmeric (Curcuma longa): A Review of Its Multifunction Health Benefits. *Holistic Nursing Practice*, **38**: 179–181.

Roy Choudhury, S., Karmakar, S., Banik, N.L., dan Ray, S.K., 2010. Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplifi. *Investigational New Drugs*, **28**: 812–824.

Ruiz-Pérez, M.V., Henley, A.B., dan Arsenian-Henriksson, M., 2017. The MYCN

UNIVERSITAS
GADJAH MADA
**Eksplorasi Aktivitas Antikanker Analog Kurkumin PGV-1 Dan CCA-1.1 Pada Sel Karsinoma Hepatoseluler
Yang Mengekspresikan MYCN**
Moordiani, Prof. Dr. apt. Ratna Asmah Susidarti, M.S.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Protein in Health and Disease. *Genes*, .

Sánchez, I. dan Dynlacht, B.D., 2005. New insights into cyclins, CDKs, and cell cycle control. *Seminars in Cell & Developmental Biology*, **16**: 311–321.

Shay, J.W. dan Roninson, I.B., 2004. Hallmarks of senescence in carcinogenesis and cancer therapy. *Oncogene*, **23**: 2919 – 2933.

Shimizu, K., Inuzuka, H., dan Tokunaga, F., 2025. The interplay between cell death and senescence in cancer. *Seminars in Cancer Biology*, **108**: 1–16.

Shin, H. dan Yu, S.J., 2025. A concise review of updated global guidelines for the management of hepatocellular carcinoma: 2017-2024. *Journal of Liver Cancer*, **25**: 19–30.

Singh, A., Sharma, S., Kumar, P., dan Garg, N., 2022. Cellular experiments to study the inhibition of c-Myc/MAX heterodimerization, dalam: *Methods in Enzymology*. hal. 193–205.

Singh, A.K., Singh, S. V, Kumar, R., Kumar, S., Senapati, S., dan Pandey, A.K., 2023. Current therapeutic modalities and chemopreventive role of natural products in liver cancer: Progress and promise. *World Journal of Hepatology*, **15**: 1–18.

Smith, H.L., Southgate, H., Tweddle, D.A., dan Curtin, N.J., 2020. DNA damage checkpoint kinases in cancer. *Expert Reviews in Molecular Medicine*, **22**: e2.

Strober, W., 2015. Trypan Blue Exclusion Test of Cell Viability. *Current Protocols in Immunology*, **111**: A3.B.1-A3.B.3.

Suenaga, Y., Einvik, C., Takatori, A., dan Zhu, Y., 2021. Editorial: Molecular Mechanisms and Treatment of MYCN-Driven Tumors. *Frontiers in Oncology*, .

Suenaga, Y., Kaneko, Y., Matsumoto, D., Hossain, M.S., Ozaki, T., dan Nakagawara, A., 2009. Positive auto-regulation of MYCN in human neuroblastoma. *Biochemical and Biophysical Research Communications*, **390**: 21–26.

Suenaga, Y., Nakatani, K., dan Nakagawara, A., 2020. De novo evolved gene product NCYM in the pathogenesis and clinical outcome of human neuroblastomas and other cancers. *Japanese Journal of Clinical Oncology*, **50**: 839–846.

Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., dkk., 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, **71**: 209–249.

Suresh, D., Srinivas, A.N., dan Kumar, D.P., 2020. Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. *Frontiers in Oncology*, **10**: 601710.

Tanaka, S., Tajiri, T., Noguchi, S.-I., Shono, K., Ihara, K., Hara, T., dkk., 2004. Clinical Significance of a Highly Sensitive Analysis for Gene Dosage and the Expression Level of MYCN in Neuroblastoma. *Journal of Pediatric Surgery*, **39**: 63–68.

Terzi, M.Y., Izmirli, M., dan Gogebakan, B., 2016. The cell fate: senescence or quiescence. *Molecular Biology Reports*, **43**: 1213–1220.

The Human Protein Atlas, 2025. 'MYCN Cell Line', . URL:

UNIVERSITAS
GADJAH MADA
**Eksplorasi Aktivitas Antikanker Analog Kurkumin PGV-1 Dan CCA-1.1 Pada Sel Karsinoma Hepatoseluler
Yang Mengekspresikan MYCN**
Moordiani, Prof. Dr. apt. Ratna Asmah Susidarti, M.S.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

https://www.proteinatlas.org/ENSG00000134323-MYCN/cell+line (diakses tanggal 2/1/2024).

The jamovi project, 2024. jamovi.

Tian, X., Yan, T., Liu, F., Liu, Q., Zhao, J., Xiong, H., dkk., 2022. Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights. *Frontiers in Pharmacology*, **13**: 991052.

Trojan, J., Zangos, S., dan Schnitzbauer, A.A., 2016. Diagnostics and treatment of hepatocellular carcinoma in 2016: Standards and developments. *Visceral Medicine*, **32**: 116–120.

Utomo, R.Y., Hapsari, N.P., Nugraheni, N., Lestari, B., Hanifa, M., Linda Laksmiani, N.P., dkk., 2025. CCA-1.1 Destabilizes MYC proteins to induce irreversible anti-proliferative effects in hepatocellular carcinoma. *Medical Oncology*, **43**: 34.

Utomo, R.Y., Wulandari, F., Novitasari, D., Lestari, B., Susidarti, R.A., Jenie, R.I., dkk., 2021. Preparation and Cytotoxic Evaluation of PGV-1 Derivative, CCA-1.1, as a New Curcumin Analog with Improved-Physicochemical and Pharmacological Properties. *Advanced Pharmaceutical Bulletin*, **12**: 603–612.

Wang, C., Zhang, J., Yin, J., Gan, Y., Xu, S., Gu, Y., dkk., 2021. Alternative approaches to target Myc for cancer treatment. *Signal Transduction and Targeted Therapy*, **6**: 117.

Wang, M.-J., Chen, F., Lau, J.T.Y., dan Hu, Y.-P., 2017. Hepatocyte polyploidization and its association with pathophysiological processes. *Cell Death and Disease*, **8**: e2805.

Wang, Y., Li, J., dan Xia, L., 2023. Plant-derived natural products and combination therapy in liver cancer. *Frontiers in Oncology*, **13**: 1116532.

Wang, Z., 2021. Regulation of Cell Cycle Progression by Growth Factor-Induced Cell Signaling. *Cells*, .

Was, H., Borkowska, A., Olszewska, A., Klemba, A., Marciniak, M., Synowiec, A., dkk., 2022. Polyploidy formation in cancer cells: How a Trojan horse is born. *Seminars in Cancer Biology*, **81**: 24–36.

Weber, L.I. dan Hartl, M., 2023. Strategies to target the cancer driver MYC in tumor cells. *Frontiers in Oncology*, **13**: 1142111.

Woo, C.-W., Tan, F., Cassano, H., Lee, J., Lee, K.C., dan Thiele, C.J., 2008. Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma. *Pediatric Blood & Cancer*, **50**: 208–212.

Wulandari, F., Ikawati, M., Kirihata, M., Kato, J.Y., dan Meiyanto, E., 2021a. A new curcumin analog, CCA-1.1, induces cell death and cell cycle arrest in WiDr colon cancer cells via ROS generation. *Journal of Applied Pharmaceutical Science*, **11**: 099–105.

Wulandari, F., Ikawati, M., Novitasari, D., Kirihata, M., Kato, J.-Y., dan Meiyanto, E., 2020. New curcumin analog, CCA-1.1, synergistically improves the antiproliferative effect of doxorubicin against T47D breast cancer cells. *Indonesian Journal of Pharmacy*, **31**: 244-256.

Wulandari, F., Ikawati, M., Widyarini, S., Kirihata, M., Novitasari, D., Kato, J.-Y., dkk., 2023. Tumour-suppressive effects of curcumin analogs CCA-1.1 and Pentagamavunone-1 in colon cancer: In vivo and in vitro studies. *Journal of*

UNIVERSITAS
GADJAH MADA
**Eksplorasi Aktivitas Antikanker Analog Kurkumin PGV-1 Dan CCA-1.1 Pada Sel Karsinoma Hepatoseluler
Yang Mengekspresikan MYCN**
Moordiani, Prof. Dr. apt. Ratna Asmah Susidarti, M.S.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Advanced Pharmaceutical Technology & Research, **14**: 317–324.

Wulandari, F., Utomo, R.Y., Novitasari, D., Ikawati, M., Kirihata, M., Kato, J.-Y., dkk., 2021b. The anti-migratory activity of a new curcumin analog, CCA-1.1, against T47D breast cancer cells. *International Journal of Pharmaceutical Research*, **13**: 11.

Xu, X.-Y., Meng, X., Li, S., Gan, R.-Y., Li, Y., dan Li, H.-B., 2018. Bioactivity, health benefits, and related molecular mechanisms of curcumin: Current progress, challenges, and perspectives. *Nutrients*, **10**: 1553.

Xu, Y., Mishra, H., Furutani, Y., Yanaka, K., Nishimura, H., Furuhata, E., dkk., 2025. A high-throughput screening platform to identify MYCN expression inhibitors for liver cancer therapy. *Frontiers in Oncology*, **15**: 1486671.

Yan, Y., Sun, Y., Li, Y., Wang, Z., Xue, L., dan Wang, F., 2025. Advancing cancer therapy: Nanomaterial-based encapsulation strategies for enhanced delivery and efficacy of curcumin. *Materials Today Bio*, **33**: 101963.

Yang, G. dan Hurlin, P.J., 2017. MNT and Emerging Concepts of MNT-MYC Antagonism. *Genes*, **8**: 83.

Yasukawa, K., Liew, L.C., Hagiwara, K., Hironaka-Mitsuhashi, A., Qin, X.-Y., Furutani, Y., dkk., 2020. MicroRNA-493-5p-mediated repression of the MYCN oncogene inhibits hepatic cancer cell growth and invasion. *Cancer Science*, **111**: 869–880.

Yilin, M., 2023. Progress on basic research and clinical evaluation of novel molecular markers of liver cancer. *Chinese Journal of Clinical Infectious Diseases*, **16**: 142–152.

Zarneshan, S.N., Fakhri, S., Bachtel, G., dan Bishayee, A., 2023. Exploiting pivotal mechanisms behind the senescence-like cell cycle arrest in cancer, dalam: *Advances in Protein Chemistry and Structural Biology*. hal. 1–19.

Zhang, Q. dan Ou, L., 2022. Recent progress in electrochemical biosensors for the detection of alpha-fetoprotein as the biomarker of liver cancer. *International Journal of Electrochemical Science*, **17**: 220734.

Zhou, Y., Li, Y., Zhou, T., Zheng, J., Li, S., dan Li, H.-B., 2016. Dietary natural products for prevention and treatment of liver cancer. *Nutrients*, **8**: 156.